IFNG and myeloid sarcoma: Our study suggests that the iP is a potential mediator of protection during chronic CNS autoimmunity following astrocyte IFNγ signaling, and identification of an endogenous inhibitor of the iP might represent a novel therapeutic target that would benefit chronic MS patients with specific patterns of neuroinflammation.